These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23381589)

  • 21. Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?
    Warren JB
    Br J Clin Pharmacol; 2013 Jan; 75(1):7-14. PubMed ID: 22574725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why are biosimilars much more complex than generics?
    Pagani E
    Einstein (Sao Paulo); 2019 Feb; 17(1):eED4836. PubMed ID: 30810585
    [No Abstract]   [Full Text] [Related]  

  • 23. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
    Walenga JM; Jackson CM; Kessler CM
    Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity.
    Schellekens H
    Eur J Clin Invest; 2004 Dec; 34(12):797-9. PubMed ID: 15606720
    [No Abstract]   [Full Text] [Related]  

  • 25. Generic drugs. Save money--but is there a cost?
    Roberts SS
    Diabetes Forecast; 2002 Nov; 55(11):51-3. PubMed ID: 14768605
    [No Abstract]   [Full Text] [Related]  

  • 26. Generic and alternative brand-name pharmaceutical equivalents: select with caution.
    Hendeles L; Hochhaus G; Kazerounian S
    Am J Hosp Pharm; 1993 Feb; 50(2):323-9. PubMed ID: 8480793
    [No Abstract]   [Full Text] [Related]  

  • 27. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 28. The end of the beginning?
    Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702
    [No Abstract]   [Full Text] [Related]  

  • 29. Making medicines safe.
    Videau JY
    Bull World Health Organ; 2001; 79(2):87. PubMed ID: 11242826
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA issues guidelines for biosimilar drugs.
    Cancer Discov; 2012 Mar; 2(3):196. PubMed ID: 22585973
    [No Abstract]   [Full Text] [Related]  

  • 31. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Woolner D
    N Z Bioeth J; 2003 Oct; 4(3):22, 25-6. PubMed ID: 15597481
    [No Abstract]   [Full Text] [Related]  

  • 32. Biosimilars in rheumatology: the wind of change.
    Schneider CK
    Ann Rheum Dis; 2013 Mar; 72(3):315-8. PubMed ID: 23390018
    [No Abstract]   [Full Text] [Related]  

  • 33. Current issues in the pioneer versus generic drug wars.
    Safir PO
    Food Drug Law J; 1995; 50(2):335-9. PubMed ID: 10343002
    [No Abstract]   [Full Text] [Related]  

  • 34. DPS--the PMA perspective.
    Beary JF; Cleveland CB
    Am Pharm; 1992 May; NS32(5):6, 8. PubMed ID: 1590210
    [No Abstract]   [Full Text] [Related]  

  • 35. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What's in a name? Generics and the persistence of the pharmaceutical brand in American medicine.
    Greene JA
    J Hist Med Allied Sci; 2011 Oct; 66(4):468-506. PubMed ID: 20858701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How to select a nanosimilar.
    Astier A; Barton Pai A; Bissig M; Crommelin DJA; Flühmann B; Hecq JD; Knoeff J; Lipp HP; Morell-Baladrón A; Mühlebach S
    Ann N Y Acad Sci; 2017 Nov; 1407(1):50-62. PubMed ID: 28715605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Adams J
    N Z Bioeth J; 2003 Oct; 4(3):22-3. PubMed ID: 15597478
    [No Abstract]   [Full Text] [Related]  

  • 39. The Challenging Future of the Biosimilars Market.
    Joseph E
    J Pharm Pract; 2016 Jun; 29(3):266-7. PubMed ID: 27169735
    [No Abstract]   [Full Text] [Related]  

  • 40. Information responsibilities of generic drug companies.
    Cramer R
    Am J Hosp Pharm; 1986 Jul; 43(7):1674, 1679. PubMed ID: 3752098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.